课题基金 / 基金详情

Screening for drugs that restore let-7 microRNA expression in cancer

Screening for drugs that restore let-7 microRNA expression in cancer
筛选恢复癌症中let-7 microRNA表达的药物
批准号:
8676736
负责人:
Richard I. Gregory
金额:
$35.02万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2012
资助国家:
美国
项目状态:
已结题
起止时间:
2012-07-11 至 2017-05-31

项目摘要

项目成果

Richard I. Gregory的其他基金

相似基金

相关文献

中文摘要
翻译
描述(申请人提供):这项提案旨在确定新发现的LIN28致癌途径的化学抑制剂,并确定这些化合物作为潜在化疗药物的有效性。Let-7microRNAs(MiRNAs)通过抑制多种癌基因的表达而发挥肿瘤抑制作用:let-7在多种肿瘤类型中表达下调,低表达与不良预后相关,在模型系统中恢复表达可有效抑制肿瘤生长。最近发现RNA结合蛋白Lin28a和Lin28b选择性地抑制let-7的表达,从而为开发新的化疗策略以恢复let-7在肿瘤中的表达提供了令人兴奋的机会。Lin28a/B正常情况下只在胚胎发育早期表达,但在约15%的人类肿瘤中异常重新激活,相应地LET-7水平降低,并且异位表达Lin28a/B促进细胞增殖和促进细胞转化。重要的是,当let-7重新导入转化细胞时,这种效应可以被取消。相反,人类癌细胞中Lin28a或Lin28b的缺失会导致细胞增殖、迁移和致瘤性下降。值得注意的是,Lin28a和Lin28b在分化较差且预后最差的肿瘤亚群中被特异性激活。Lin28a招募Zcchc11,一种新的3‘末端尿苷酰转移酶(TUTase)来阻止let-7的生物发生。因此,Lin28a-TUTase代表了癌症治疗的一个重要新靶点。新的高通量筛选(HTS)方法将被开发并用于识别在表达Lin28a的癌症中恢复let-7表达的药物。HTS将使用两种互补的检测方法:一种是基于细胞的系统,用于监测let-7的表达;另一种是生化检测,用于识别TUTase的抑制剂。HIT化合物将使用一系列二次筛选进行验证,并将检查这些化合物对癌细胞增殖的影响。这种方法将把基础科学发现转化为开发新的有效的癌症治疗方法。
英文摘要
DESCRIPTION (provided by applicant): This proposal aims to identify chemical inhibitors of the newly discovered Lin28 oncogenic pathway, and to establish the efficacy of these compounds as potential chemotherapeutics. let-7 microRNAs (miRNAs) function as tumor suppressors by inhibiting the expression of several oncogenes: let-7 is downregulated in numerous tumor types, low let-7 correlates with poor prognosis, and restoration let-7 expression effectively inhibits cancer growth in model systems. It was recently found that the RNA-binding proteins Lin28A and Lin28B selectively inhibit expression of let-7 and thus provides an exciting opportunity for the development of novel chemotherapeutic strategies to restore let-7 expression in cancer. Lin28A/B are normally only expressed during early embryonic development but is aberrantly reactivated in ~15% of human cancers, with a corresponding reduction in let-7 levels, and ectopic Lin28A/B expression enhances cell proliferation and promotes cellular transformation. Importantly, this effect can be abrogated when let-7 is reintroduced into the transformed cells. Conversely, depletion of Lin28A or Lin28B in human cancer cells lines results in decreased cell proliferation, migration, and tumorigenicity. Strikingly, Lin28A and Lin28B are specifically activated in the subset of tumors that are poorly differentiated and carry the worst prognosis. Lin28A recruits Zcchc11, a novel 3' terminal uridylyl transferase (TUTase) to block let-7 biogenesis. Thus Lin28A-TUTase represents an important new target for cancer treatment. Novel high-throughput screening (HTS) approaches will be developed and utilized to identify drugs that restore let-7 expression in Lin28A-expressing cancers. Two complementary assays will be utilized for HTS: a cell-based system to monitor let-7 expression, and a biochemical assay to identify inhibitors of the TUTase. Hit compounds will be validated using a series of secondary screens and the effect of these compounds on cancer cell proliferation will be examined. This methodology will translate basic science discoveries to the development of new and effective cancer treatments.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of the Epitranscriptome in Cancer
  • 批准号:
    10450108
  • 项目类别:
  • 资助金额:
    $104.08万
  • 财政年份:
    2019
  • 负责人:
    Richard I. Gregory
  • 依托单位:
Role of the Epitranscriptome in Cancer
  • 批准号:
    10219192
  • 项目类别:
  • 资助金额:
    $106.2万
  • 财政年份:
    2019
  • 负责人:
    Richard I. Gregory
  • 依托单位:
Role of METTL3 and the m6A Epitranscriptome in cancer
  • 批准号:
    10520012
  • 项目类别:
  • 资助金额:
    $63.06万
  • 财政年份:
    2019
  • 负责人:
    Richard I. Gregory
  • 依托单位:
Role of the Epitranscriptome in Cancer
  • 批准号:
    9979795
  • 项目类别:
  • 资助金额:
    $106.2万
  • 财政年份:
    2019
  • 负责人:
    Richard I. Gregory
  • 依托单位:
海外基金